{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-023226","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.379089+00:00","generated_at":"2026-06-22T03:41:22.261474+00:00","sec_items":["2.02","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Atara gets positive CHMP opinion for Ebvallo; Q3 net loss $84.1M","bullets":["CHMP positive opinion for Ebvallo in EBV+ PTLD; EC approval expected by end 2022.","Cash $265.4M; expects operating runway into Q1 2024 with Pierre Fabre milestone.","Q3 net loss $84.1M ($0.82/diluted share) vs $84.7M ($0.90) YoY; R&D $70.2M.","ATA188 MRI data show less brain atrophy, potential remyelination in progressive MS patients with CDI.","Tab-cel safety consistent; ORR 51.2% in Phase 3 ALLELE; seeking US commercialization partner."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-023226","json":"https://secwatch.observer/filing/0000950170-22-023226.json","markdown":"https://secwatch.observer/filing/0000950170-22-023226.md","text":"https://secwatch.observer/filing/0000950170-22-023226.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000095017022023226/0000950170-22-023226-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000095017022023226/atra-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:41:22.261474+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"51ae998762539504e0b391daa148721e6f6047ba","claim":"Atara Biotherapeutics, Inc. reported financial results for the third quarter 2022.","evidence_excerpt":"Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the third quarter 2022, recent business highlights, and key upcoming catalysts.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604464/000095017022023226/0000950170-22-023226-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}